Sci102 - 01 Feb 2025 - 14:00:29 - 17113 of 17352 Scancell - Pot of Gold or POS? - SCLP
Which one has failed?
Well, keytruda is successful beyond any doubt. SCIB1 has been in clinical development for 355 years more or less, to the point where patents have expired. So yeah, scib1 is infinitely closer to failure than Keytruda, why don't you stop asking that stupid question already? |
SC102 ... mr Gobby .......... well he can't answer that
and why did Mr Gobby buy 100,000 shares recently |
many are convinced "no Risk" is wrong ...... same as "all in"
but if you have read the research
how can that be ?
our T cells are proven
ATB
and nobody that declares RISK can answer
"well which one has failed"
since 2015 |
Ivy laid the claim that He understands this industry...
really ?
you guys demand "proven" in trial
but the funny part
in life you are un-proven compared to what you claim
because there are no Stand out "wow" in any post i have seen ...
but you still convince yourself everyone agrees with you !! |
I agree goyathlay...
.
Ruck...I think it's fair to assume if it's calculus they know more than 'most' investors.
But I don't think 'insider knowledge' is of any use anyhow....
And...I did say they don't 'expect' the share price to rise ..
That's because calculus or any other big investor really won't have a clue anyway.
Tykey is always intellectually honest.. |
its you Ruck that laid the claim of being a Data Scientist ...
nobody else diagnosed you ...
but what did you discover ?
an anomaly !! |
Inan will kick off against anyone
really ? Ruck
Mia no
Marcus No
loads of posters don't have a problem
but you and your bully boys try to imprint the market with twisted nonsense
Bermuda Has dumped you and Ivy .. he does not reply to you anymore
but if Bermuda cannot accept any fact presented because he has to "face save"
well that is his problem not mine
he promotes Risk ... but cannot quantify
your problem is not my arrogance but your ignorance
i had to explain to you about High Avidity
you ""COULD NOT DO IT YOURSELF""
and that is YOUR problem
I am doing it for Profit .......... 1.7m shares
posting gives me different avenues of research and considerations
so I did research GSK and Oxford
along with Ivy's company research, which he did not even know about !!!!
but then why would a salesman need to know that |
I would short The Orangutan's and Melon Ears' 'conflict of interest tokens' and Musktard's dodgems.
Let's show some solidarity with this example of cross-border synergy. |
anyway you can't afford a CFD turkey so Fk off |
2tyke, "When a large investor ( with inside knowledge)"You don't know for sure who the large investor is but we suspect it's calculus. Even so, you certainly don't know if they have insider knowledge or not. It's all about intellectual honesty so you keep telling us. Try and show some yourself. |
so when scancell predicted a 90% chance that we could achieve 70% success from 13 to 43 scale
does that affect the calculation ... 3% ?
now
if we have treated 40, 43,43,43,43 in the scope trials different arms
and they work
whats the odds that translates in a 200 patient phase 3 ....approval ?
sales $3.8b
whoever partners i suspect will run an adjuvant trial concurrent ..... which controls the baseline of all high risk melanoma patients
rising to $9billion
Bitcoin ... No dividend dead money |
In the stock market PRICE is king...
It is EVERYTHING...
.
That's 9p...
.
Down 2/3 on successful trials and genmab deals.
.
When a large investor ( with inside knowledge).. |
No non approved...
And your jumping around rubbing your hands together ...thinking you even understand scientific risk...lol
.
We won't even go there with your total ignorance of stock market risk.
As your Bitcoin comment shows....you don't understand prices at all...
.
Rather glad your in your own world with no-one except the bizarre Tf reading....lol |
yes more than £8 a share 🤣🤣🤣🤣 |
i can give you the numbers Turkey
Oncology .............. pass rate 3%
that is 97% of the money invested in cancer research is lost .....or used to develop further understanding
but what is the 3% worth ......? |
as explained "tons of work"
how many approvals ? |
another RNS from Trump ... Chinese tariff
Bitcoin Down
PMSL
no elliots involved |
There's tons of this kind of work going on.
Are you trying to 'convince' yourself of something ? Are you brain-washed ?
.
.
Everything works in theory.. see me things even work (to a degree) in practice.
.
.
You can easily assess 'interest' though ..
Most of the successful scancell trials have been done over the past 2-3 years, including 2/3 deals.
The share price has lost 2/3 of its value....
Things move on. |
anyway that is why i feel i am capable of Assessing risk
because all the research is scancell focused on the stuff that actually matters the science |
so all this data gathering is ongoing ....
"this is what Big pharma want to see"
the nitty gritty .... stuff
total boring for investors
but its like Lindy Said at the dinner table nobody was interested in T cells and antibodies
until
Covid arrived
MRNA has managed to sell itself on that basis
but is it good enough for cancer without going down the highly expensive route of personal vaccines and even then does it work to the level to justify the cost to the mass market
I think its been over sold by the media ...An image imprinted of unproven capability |
Inan, "now if you still think i am an idiot ...."No, I've never said you are an idiot. |
one other thing Ruck ....
when you test for Avidity ... like what you posted they cultured the t cells
this is a early email with lindy
Re yes we did trial this kit but it could not read out avidity on our mouse T cells. In the human trial this is more difficult as we culture the T cells which can change their avidity. We have identified some specific TCRs from both SCOPE and Modify and we will now start measuring avidity.
Kind Regards,
lindy |
Immunobody ....
Goes DIRECT to APC
the mabs go only to the C64 on the APC that are involved in "inflammation"
and can control t cell function
to fight cancer
tick tock
It works |
the CD64 also controls which Dendritic cells to go after
Distinguishing marker:
CD64 expression can be used to differentiate between different types of dendritic cells, particularly helping to distinguish monocyte-derived dendritic cells from conventional dendritic cells.
AI Overview
Learn more
Pharmacological potentiation of monocyte-derived dendritic ...
Monocyte-derived dendritic cells (moDCs) are a type of antigen-presenting cell (APC) that can help the body's immune system fight cancer. They are a key component of anti-cancer DC vaccines, which are used to treat metastatic melanoma and other types of cancer. |
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Hot Features
Premium
